Arteriosclerosis Thrombosis and Vascular Biology Journal Citation Rate 2026
1079-5642
eISSN 1524-4636
Ovid Technologies (Wolters Kluwer)
US
Q2 Quartile Established Impact
About Arteriosclerosis Thrombosis and Vascular Biology
Arteriosclerosis Thrombosis and Vascular Biology (ATVB) is a peer-reviewed academic journal, published by Ovid Technologies (Wolters Kluwer) in US, catalogued under ISSN 1079-5642 (e-ISSN 1524-4636). As of 2026, it has a 2023 2-Year Citation Rate (OpenAlex) of 2.27 (Q2 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model.
Authors typically receive a first decision in around 67 days.
Arteriosclerosis Thrombosis and Vascular Biology Citation Rate 2026 — In Context
Arteriosclerosis Thrombosis and Vascular Biology has a 2023 2-Year Citation Rate (OpenAlex) of 2.27, placing it in the Q2 quartile. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Arteriosclerosis Thrombosis and Vascular Biology operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view. Average submission-to-decision turnaround is approximately 67 days.
Researchers looking to publish in Arteriosclerosis Thrombosis and Vascular Biology should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Arteriosclerosis Thrombosis and Vascular Biology against similar journals in the field, use our journal comparison tool.
Submission Tips for Arteriosclerosis Thrombosis and Vascular Biology
- Be prepared for a longer review cycle — decisions typically take around 67 days.
| ISSN (Print) | 1079-5642 |
|---|---|
| ISSN (Online) | 1524-4636 |
| Publisher | Ovid Technologies (Wolters Kluwer) |
| Country | United States |
| APC / Cost | Inquire with Publisher |
| Review Speed | ~67 days to first decision |
In-depth profile & metrics
Arteriosclerosis Thrombosis and Vascular Biology is published by Ovid Technologies (Wolters Kluwer) and based in United States.
For prospective authors, Arteriosclerosis Thrombosis and Vascular Biology returns a first decision in about 67 days (longer for its field).
Its most recent citation rate stands at 2.270.
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Arteriosclerosis Thrombosis and Vascular Biology
Live Indexing Status
Updated March 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2023 | 2.270 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Journal Metrics
Explore More Journals
Metadata
Last updated: Mar 20, 2026
Updated by: system
Get weekly updates
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.